How Much Improvement in Functional Status Is Considered Important by Patients With Active Psoriatic Arthritis: Applying the Outcome Measures in Rheumatoid.

Slides:



Advertisements
Similar presentations
ASSESSING RESPONSIVENESS OF HEALTH MEASUREMENTS. Link validity & reliability testing to purpose of the measure Some examples: In a diagnostic instrument,
Advertisements

Psoriatic Arthritis: Creating a Model for Cost- Effectiveness Analysis GRAPPA meeting San Antonio, TX October 15, 2004 Supported by Schering Participants:
The Cost-Effectiveness and Value of Information Associated with Biologic Drugs for the Treatment of Psoriatic Arthritis Y Bravo Vergel, N Hawkins, C Asseburg,
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
1 Health-Related Quality of Life Ron D. Hays, Ph.D. - UCLA Department of Medicine: Division of General Internal Medicine.
Assessment of Lupus (SLE) Mortality in a Patient-Based Community Data Bank Frederick Wolfe 1, Kaleb Michaud 1,2, Tracy Li 3, Robert S. Katz 4 1 National.
GRAPPA Examples of Work Projects Philip Mease. Examples of GRAPPA Work Projects Classification and diagnosis of PsA (CASPAR) Evaluation of PsA composite.
Quality Measures for Rehabilitation: Policy, Provider and Patient Perspectives Measuring Clinical Change: Quality Indicators ACRM-ASNR Pre-Conference Institute.
Is the Minimally Important Difference Really 0.50 of a Standard Deviation? Ron D. Hays, Ph.D. June 18, 2004.
Power and Sample Size Determination Anwar Ahmad. Learning Objectives Provide examples demonstrating how the margin of error, effect size and variability.
OUTCOME MEASURES IN PsA: TISSUE ANALYSIS Oliver FitzGerald.
GRAPPA Evidence-Based Treatment Guidelines for Psoriatic Arthritis. Peripheral joint disease Dr. Enrique R. Soriano Dr. Neil J. McHugh.
1 Assessing the Minimally Important Difference in Health-Related Quality of Life Scores Ron D. Hays, Ph.D. UCLA Department of Medicine October 25, 2006,
EVIDENCE ABOUT DIAGNOSTIC TESTS Min H. Huang, PT, PhD, NCS.
Correlation and Prediction Error The amount of prediction error is associated with the strength of the correlation between X and Y.
TAP PHARMACEUTICAL PRODUCTS INC. June 2, Arthritis Drugs Advisory Committee TAP Pharmaceutical Products Inc. June 2, 2004.
What makes difficult asthma difficult? SCH Journal Club Nicki Barker 2012 June 2012 Dysfunctional breathing in children1.
Causal relationships, bias, and research designs Professor Anthony DiGirolamo.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
1 Session 6 Minimally Important Differences Dave Cella Dennis Revicki Jeff Sloan David Feeny Ron Hays.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Assessing Responsiveness of Health Measurements Ian McDowell, INTA, Santiago, March 20, 2001.
SARAH: Strengthening and Stretching for Rheumatoid Arthritis Affecting the Hand: A randomised controlled trial Adams J, Williams MA, Heine PJ, McConkey.
Outcome Measures in PsA Philip Mease MD Seattle, WA.
Patient-Reported Physical Functioning Ron D. Hays November 27, 2012 (11:15-11:30) UCLA Department of Medicine MCID for Orthopaedic Devices Silver Springs,
Health-Related Quality of Life in Outcome Studies Ron D. Hays, Ph.D UCLA Division of General Internal Medicine & Health Services Research GCRC Summer Session.
GRAPPA Committee Reports and Outcome measures Dafna D. Gladman, MD, FRCPC Professor of Medicine, University of Toronto Director, PsA Program, University.
Copyright © 2003 American Medical Association. All rights reserved.
SAT0699 Rapid assessment predicts disease activity improvement in newly diagnosed Rheumatoid Arthritis (RA) Mark Yates*, James Galloway, Neil Snowden,
Copyright © 2014 American Medical Association. All rights reserved.
Ann Intern Med. 1999;130(6): doi: / Figure Legend:
Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.
Geir Smedslund, Ph.D.: Diakonhjemmet Hospital (DH)
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.
Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis  Alice B. Gottlieb, MD, PhD,
Amy S. Paller, MD, Elaine C. Siegfried, MD, David M
Volume 74, Issue 5, Pages (November 2018)
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.
Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)
EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE
(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI
Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.
Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.
HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.
Volume 121, Issue 5, Pages (November 2001)
OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,
OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed data. OR for selected baseline predictors.
Percentage of patients reporting improvements ≥MCID and NNTs to achieve an MCID in (A) PtGA, (B) pain, (C) HAQ-DI, (D) FACIT-F and (E) SF-36 domains and.
Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.
Clinical response in patients with early and established RA at month 24. *p
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.
Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.
Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.
Percentage of patients with RA achieving DAS28(CRP)<2
Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.
Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA.
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.
Estimating Minimally Important Differences (MIDs)
(A) Mean (95% CI) change and (B) mean percentage (SE) change in enthesitis scores (Leeds Enthesitis Index, SPARCC Enthesitis Index, and MASES) from baseline.
Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.
Presentation transcript:

How Much Improvement in Functional Status Is Considered Important by Patients With Active Psoriatic Arthritis: Applying the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Group Guidelines Philip Mease 1 Rita Ganguly 2, L. Wanke 3, Amitabh Singh 2 1 Seattle Rheumatology Associates, Seattle, WA; 2 Wyeth Research, Collegeville, PA; 3 Amgen, Thousand Oaks, CA

Objectives To estimate MCID based on OMERACT Group recommendation, for characterizing between- treatment group, within-group, and within-subject improvements in functional status of patients with Psoriatic Arthritis (PsA)

Methods Data from a double blind, randomized, placebo controlled 24 weeks study was used to assess patients with active Psoriatic Arthritis treated with etanercept 25 mg twice weekly compared to placebo Alternative measures of MCID for improvement in patients’ functional status as measured by Health Assessment Questionnaire (HAQ) were: –Data-driven MCID: –Patient Rating-Based MCID: –Patient Rating-Based Important MCID: 2.1.5

Methods Data-Driven Approach MCID Upper bound of 95% confidence interval of standard error of measurement (SEM) for HAQ SEM = σ baseline HAQ 1- r baseline HAQ where σ=standard deviation r = Cronbach’s alpha coefficient

Methods Patient Rating-Based MCID How important to you is the amount of change in your physical limitations (such as limitations in walking, standing, gripping reaching, etc.) Not AtExtremely All Important Important Mean change from baseline in HAQ Disability Score for those who improved Minimally Important Very Important

GroupsAgeHAQDuration Etanercept years Placebo years Results Baseline Characteristics

Results

Mean Change of HAQ Scores from Baseline were Clinically Meaningful for Patients Treated with Etanercept 25 mg twice weekly

Results Weeks Percent Percent Achieving SEM Based MCID in HAQ Threshold

Conclusions Improvements of 0.30 in HAQ score are considered “minimally important” by patients with active PsA. A threshold of 0.30 may be used to characterize within- treatment group changes in the HAQ Disability Index. A higher threshold of 0.40 should be used to characterize within-subjects improvements in the HAQ Disability Index.

Valued Life Activities (VLA) Broader array of activities than measured by HAQ, e.g. ability to take part in social activities, taking care of family members, participating in religious activities, etc. Element of motivation Importance of meaningfulness

VLA Katz P Arth Care & Research 1995 RA patients with decline in basic function and/or loss of valued activities Deline in basic function (HAQ), no loss of valued activities (30%) Loss of valued activities, no decline in basic function (57%) Both (13%)